Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease

Published:2001-04 Issue:4 Volume:15 Page:463-473
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

Cornillie F.,Shealy D.,D'Haens G.,Geboes K.,Van Assche G.,Ceuppens J.,Wagner C.,Schaible T.,Plevy S. E.,Targan S. R.,Rutgeerts P.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2036.2001.00956.x/fullpdf

Reference14 articles.

1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease;Targan;N Engl J Med,1998

2. Infliximab for the treatment of fistulas in patients with Crohn’s disease;Present;N Engl J Med,1999

3. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis;Baert;Gastroenterology,1999

4. A role for TNFα mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease;Plevy;J Immunol,1997

5. Endoscopic and histological healing with infliximab tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial;D'Haens;Gastroenterology,1999

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infliximab in Inflammatory Bowel Disease: Leveraging Physiologically Based Pharmacokinetic Modeling in the Clinical Context;Biomedicines;2024-09-01

2. Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing;Molecular Therapy;2024-08

3. What is the impact of biologics on the management of the oral surgery patient?;British Dental Journal;2024-04-26

4. Racial Disparities in Infliximab Efficacy for Ulcerative Colitis: Evidence Synthesis and Effect Modification Assessment;Journal of Clinical Medicine;2024-01-05

5. Monoclonal Antibodies: From Structure to Therapeutic Application;Pharmaceutical Biotechnology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3